Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDCarisma Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.57 | -$0.32 | -$0.43 |
| Q2 2024 | 1 | -$0.39 | -$0.22 | -$0.30 |
| Q3 2024 | 1 | -$0.41 | -$0.23 | -$0.32 |
| Q4 2024 | 2 | -$0.23 | -$0.13 | -$0.18 |
| Q1 2025 | 1 | -$0.23 | -$0.13 | -$0.17 |
| Q2 2025 | 1 | -$0.16 | -$0.09 | -$0.12 |
| Q3 2025 | 1 | -$0.19 | -$0.11 | -$0.15 |
| Q4 2025 | 1 | -$0.22 | -$0.12 | -$0.17 |
| Q1 2026 | 1 | -$0.21 | -$0.11 | -$0.16 |
| Q2 2026 | 1 | -$0.18 | -$0.10 | -$0.14 |
| Q3 2026 | 1 | -$0.20 | -$0.11 | -$0.15 |
| Q4 2026 | 1 | -$0.22 | -$0.12 | -$0.17 |
| Q1 2027 | 1 | -$0.19 | -$0.11 | -$0.15 |
| Q2 2027 | 1 | -$0.17 | -$0.10 | -$0.13 |
| Q3 2027 | 1 | -$0.19 | -$0.10 | -$0.14 |
| Q4 2027 | 1 | -$0.21 | -$0.12 | -$0.16 |
| Q1 2028 | 1 | -$0.18 | -$0.10 | -$0.14 |
| Q2 2028 | 1 | -$0.17 | -$0.10 | -$0.13 |
| Q3 2028 | 1 | -$0.19 | -$0.10 | -$0.14 |
| Q4 2028 | 1 | -$0.21 | -$0.12 | -$0.16 |
Carisma Therapeutics, Inc. Earnings Date And Information
Carisma Therapeutics, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.31 earnings per share for the quarter, missing analysts' consensus estimates of $-0.31 by $0. The company had revenue of 3.39 M for the quarter and had revenue of 14.92 M for the year. Carisma Therapeutics, Inc. has generated $-3 earnings per share over the last year ($-2.59 diluted earnings per share) and currently has a price-to-earnings ratio of -0.27. Carisma Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, April 7th, 2025 based on prior year's report dates.
Carisma Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$0.31 | -$0.31 | 0 | $5.47 M | $3.39 M |
| 08/08/2024 | Q2 2024 | -$0.36 | -$0.27 | 0.09 | $3.92 M | $9.20 M |
| 05/09/2024 | Q1 2024 | -$0.46 | $3.40 M | |||
| 04/01/2024 | Q4 2023 | -$0.56 | -$0.52 | 0.04 | $4.29 M | |
| 09/29/2023 | Q3 2023 | -$0.53 | $1.19 M | $3.83 M | ||
| 06/30/2023 | Q2 2023 | -$0.49 | $1.08 M | $3.56 M | ||
| 03/31/2023 | Q1 2023 | -$1.93 | $3.24 M | |||
| 02/28/2023 | Q4 2022 | -$2.20 | $1.21 | 3.41 | $3.73 M | |
| 11/07/2022 | Q3 2022 | -$3.10 | -$0.46 | 2.64 | $2.58 M | |
| 08/08/2022 | Q2 2022 | -$2.60 | -$1.10 | 1.5 | $2.70 M | |
| 05/09/2022 | Q1 2022 | -$2.00 | -$0.32 | 1.68 | $822,000 | |
| 02/28/2022 | Q4 2021 | -$1.47 | $0.90 | 2.37 | $20.00 M | |
| 11/08/2021 | Q3 2021 | -$1.40 | $7.28 | 8.68 | $533,333 | $0 |
| 08/09/2021 | Q2 2021 | -$1.27 | -$2.90 | -1.63 | $2.23 M | |
| 05/10/2021 | Q1 2021 | -$1.53 | -$7.07 | -5.54 | $4.31 M | |
| 03/15/2021 | Q4 2020 | -$2.13 | -$2.55 | -0.42 | $0 | |
| 11/09/2020 | Q3 2020 | -$1.60 | -$3.84 | -2.24 | $11.24 M | |
| 08/10/2020 | Q2 2020 | -$1.87 | -$4.68 | -2.81 | $0 | |
| 05/11/2020 | Q1 2020 | -$1.73 | $7.57 | 9.3 | $0 | |
| 03/16/2020 | Q4 2019 | -$1.67 | -$6.11 | -4.44 | $0 |
Carisma Therapeutics, Inc. Earnings: FAQ's
When is Carisma Therapeutics, Inc.'s earnings date?
Carisma Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, April 7th, 2025 based off last year's report dates.
How can I listen to Carisma Therapeutics, Inc.'s earnings conference
call?
The conference call for Carisma Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read Carisma Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Carisma Therapeutics, Inc.'s latest earnings report can be read online.
How much revenue does Carisma Therapeutics, Inc. generate each year?
Carisma Therapeutics, Inc. (:CARM) has a recorded annual revenue of $14.92 M.
How much profit does Carisma Therapeutics, Inc. generate each year?
Carisma Therapeutics, Inc. (:CARM) has a recorded net income of $14.92 M. Carisma Therapeutics, Inc. has generated $-2.59 earnings per share over the last four quarters.
What is Carisma Therapeutics, Inc.'s price-to-earnings ratio?
Carisma Therapeutics, Inc. (:CARM) has a price-to-earnings ratio of -0.27 and price/earnings-to-growth ratio is -0.02.